Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
1,235
datasets available to search
ShareScore release 0.7.1
Dataset results
1,235 results for “pulmonary hypertension”
Data described in the article "Glycopolymer Inhibitors of Galectin-3 Suppress the Markers of Tissue Remodeling in Pulmonary Hypertension"
<p>The dataset includes supplementary data, i.e. experimental data, tables, and figures detailing the synthetic procedures, compound characterization, binding assays, and cell culture studies of the study titled "Glycopolymer Inhibitors of Galectin‑3 Suppress the Markers of Tissue Remodeling in Pulmonary Hypertension" available here: https://doi.org/10.1021/acs.jmedchem.4c00341</p>
Blood DNA Methylation Profiling Identifies Cathepsin Z Dysregulation in Pulmonary Arterial Hypertension
<p>Ulrich, A., Wu, Y., Draisma, H., Wharton, J., Swietlik, E. M., Cebola, I., Vasilaki, E., Balkhiyarova, Z., Jarvelin, M. R., Auvinen, J., Herzig, K. H., Coghlan, J. G., Lordan, J., Church, C., Howard, L. S., Pepke-Zaba, J., Toshner, M., Wort, S. J., Kiely, D. G., Condliffe, R., … Rhodes, C. J. (2024). <a href="https://pubmed.ncbi.nlm.nih.gov/38184627/"><strong>Blood DNA methylation profiling identifies cathepsin Z dysregulation in pulmonary arterial hypertension</strong></a>. <em>Nature communications</em>, <em>15</em>(1), 330. https://doi.org/10.1038/s41467-023-44683-0</p> <p>Maternal educational attainment (MEA) shapes offspring health through multiple potential pathways. Differential DNA methylation may provide a mechanistic understanding of these long-term associations. We aimed to quantify the associations of MEA with offspring DNA methylation levels at birth, in childhood and in adolescence. Using 37 studies from high-income countries, we performed meta-analysis of epigenome-wide association studies (EWAS) to quantify the associations of completed years of MEA at the time of pregnancy with offspring DNA methylation levels at birth (n = 9 881), in childhood (n = 2 017), and adolescence (n = 2 740), adjusting for relevant covariates. MEA was found to be associated with DNA methylation at 473 cytosine-phosphate-guanine sites at birth, one in childhood, and four in adolescence. We observed enrichment for findings from previous EWAS on maternal folate, vitamin-B12 concentrations, maternal smoking, and pre-pregnancy BMI. The associations were directionally consistent with MEA being inversely associated with behaviours including smoking and BMI. Our findings form a bridge between socio-economic factors and biology and highlight potential pathways underlying effects of maternal education. The results broaden our understanding of bio-social associations linked to differential DNA methylation in multiple early stages of life. The data generated also offers an important resource to help a more precise understanding of the social determinants of health.</p>
Data manuscript: Preventive training does not interfere with mRNA-encoding myosin and collagen expression during pulmonary arterial hypertension
<p>Supporting Information files of manuscript: Preventive training does not interfere with mRNA-encoding myosin and collagen expression during pulmonary arterial hypertension </p> <p> </p> <p>The values behind the means, standard deviations and values used to build graphs; </p>
Effects of the oral angiotensin II type 2 receptor agonist C21 in Sugen-hypoxia induced pulmonary hypertension in rats
<p><span><span>Substantial evidence supports involvement of the renin-angiotensin system in pulmonary hypertension (PH), and the angiotensin II type 2 receptor (AT<sub>2</sub>R) is known to exert tissue-protective actions. The effect of the selective AT<sub>2</sub>R agonist C21 (also known as Compound 21 or buloxibutid) was evaluated in the rat Sugen-hypoxia PH model. After a single injection of Sugen 5416 and hypoxia for 21 days, </span><span>C21</span><span> (2 or 20 mg/kg) or vehicle was administered perorally twice daily from Day 21 to Day 55. On Day 56, hemodynamic assessments were performed, and lung and heart tissue were prepared for quantification of cardiac and vascular remodeling and fibrosis. Treatment with C21 20 mg/kg improved cardiac output and stroke volume and decreased right ventricular hypertrophy (all p<0.05). Treatment with C21 2 mg/kg significantly decreased vessel wall and muscular layer thickness and increased the luminal opening in vessels >100 </span><span>μ</span><span>m (all p<0.05). There were no significant differences between the two C21 doses on any parameter, and <em>post hoc</em> analyses </span><span>comparing the merged C21 groups with the vehicle group showed that C21 treatment reduced vascular remodeling (reduced endothelial proliferation and thickening of the vascular wall) in vessels of all sizes; moreover, the diastolic pulmonary artery pressure and right ventricular pressure were reduced along with reduction of right ventricular hypertrophy. Sugen 5416 and hypoxia increased pulmonary collagen deposition, which was counteracted by C21 20 mg/kg. In conclusion, the effects of C21 on vascular remodeling, hemodynamic alterations, and fibrosis suggest that AT<sub>2</sub>R agonists may have a role in Group 1 and 3 PH treatment.</span><br></span></p>
Lipidomics for diagnosis and prognosis of pulmonary hypertension
<p>Pulmonary hypertension (PH) is associated with high morbidity and mortality with an urgent need for diagnostic and prognostic biomarkers.</p> <p>A training cohort of PH patients, disease controls without PH, and healthy controls was investigated using metabolomics and machine learning. Specific free fatty acid (FFA)/lipid-ratio biomarkers were diagnostic and predictive for PH survival with an area under the curve (AUC) of 0.89. FFA/lipid-ratio performance was independently validated in PH patients from other centers(AUC 0.90). Survival could be predicted in an age-independent manner and a combination with established clinical scores (FPHR4p, COMPERA 2.0) increased the scores hazard risk.</p> <p>Our mechanistic studies in healthy and diseased pulmonary artery endothelial and smooth muscle cells indicate a functional involvement of increased FFA levels in pathophysiology of PH. In conclusion, lipidomic changes in PH can be used as a novel diagnostic and prognostic approach and may help the discovery of new therapeutic targets.</p>
Clinical Investigation Into Inhaled Treprostinil Sodium in Patients With Severe Pulmonary Arterial Hypertension (PAH)
ClinicalTrials.gov study NCT00147199. IPD Sharing: Not stated. Countries: 10. Publications: 1.
Ambrisentan in Patients With Porto-pulmonary Hypertension A Multicenter Open Label Trial
ClinicalTrials.gov study NCT01224210. IPD Sharing: NO. Countries: 1. Publications: 1.
ARTEMIS-PH - Study of Ambrisentan in Subjects With Pulmonary Hypertension Associated With Idiopathic Pulmonary Fibrosis
ClinicalTrials.gov study NCT00879229. IPD Sharing: Not stated. Countries: 7. Publications: 1.
Pulmonary Hypertension and Anastrozole Trial
ClinicalTrials.gov study NCT03229499. IPD Sharing: Not stated. Countries: 1. Publications: 1.
A Clinical Trial of Ambrisentan and Tadalafil in Pulmonary Arterial Hypertension Associated With Systemic Sclerosis
ClinicalTrials.gov study NCT01042158. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Auto-PAP for Pulmonary Hypertension Treatment in Decompensated HF Patients With Sleep Apnea.
ClinicalTrials.gov study NCT02963597. IPD Sharing: NO. Countries: 2. Publications: 1.
Ranolazine and Pulmonary Hypertension
ClinicalTrials.gov study NCT01174173. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Study to Assess the Tolerability and the Safety of the Transition From Inhaled Treprostinil to Oral Selexipag in Patients With Pulmonary Arterial Hypertension
ClinicalTrials.gov study NCT02471183. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Assess the Efficacy and Safety of Sildenafil When Added to Bosentan in the Treatment of Pulmonary Arterial Hypertension
ClinicalTrials.gov study NCT00323297. IPD Sharing: Not stated. Countries: 10. Publications: 1.
PH-DyPred: A Multimodal Dynamic Risk Prediction Study in Pulmonary Hypertension
ClinicalTrials.gov study NCT07131241. IPD Sharing: YES. Countries: 1. Publications: 12.
Extension to CQTI571A2102 to Evaluate Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)
ClinicalTrials.gov study NCT01392495. IPD Sharing: Not stated. Countries: 7. Publications: 2.
Simvastatin as a Treatment for Pulmonary Hypertension
ClinicalTrials.gov study NCT00180713. IPD Sharing: NO. Countries: 2. Publications: 1.
Early Treatment of Borderline Pulmonary Arterial Hypertension Associated With Systemic Sclerosis (SSc-APAH)
ClinicalTrials.gov study NCT02290613. IPD Sharing: Not stated. Countries: 1. Publications: 3.
PAHTCH Pulmonary Arterial Hypertension Treatment With Carvedilol for Heart Failure (Carvedilol)
ClinicalTrials.gov study NCT01586156. IPD Sharing: Not stated. Countries: 1. Publications: 5.
Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)
ClinicalTrials.gov study NCT02138825. IPD Sharing: Not stated. Countries: 21. Publications: 1.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.